Sagimet Biosciences (SGMT, Financial) has announced that it will showcase three significant poster presentations at the European Association for the Study of Liver Congress 2025, taking place from May 7-10 in Amsterdam. These presentations will highlight additional data from the Phase 2b FASCINATE-2 study concerning denifanstat's impact on metabolic dysfunction-associated steatohepatitis (MASH).
Among the research being presented is an analysis of the MASH Resolution Index (MR-I), a non-invasive biomarker score. This retrospective study from the FASCINATE-2 trial indicated the MR-I's potential to predict the histologic resolution of MASH in patients treated with denifanstat, and possibly identify non-responders. Researchers are also exploring the MR-I as a less invasive alternative to traditional liver biopsy for determining treatment outcomes.
Another key presentation focuses on the effects of denifanstat on plasma bile acids. The study observed significant reductions in glycine- and taurine-conjugated bile acids among denifanstat-treated MASH patients over a 26-week period. These reductions correlated with histological improvements, suggesting these bile acids could serve as biomarkers for treatment response.
Additionally, the congress will feature findings on the antifibrotic effects of denifanstat, which were examined using qFibrosis-based collagen features linked to adverse liver outcomes. Notably, pronounced antifibrotic responses were identified in patients with high polygenic risk factors when treated with denifanstat, highlighting the potential benefits for those at higher risk.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Sagimet Biosciences Inc (SGMT, Financial) is $31.14 with a high estimate of $67.00 and a low estimate of $5.00. The average target implies an upside of 1,121.29% from the current price of $2.55. More detailed estimate data can be found on the Sagimet Biosciences Inc (SGMT) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Sagimet Biosciences Inc's (SGMT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
